E.L. Kwak

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

John Souglakos, Juliet Philips, R Wang et al. · British Journal of Cancer · 2009 · 317 citations · Full text

The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene.

Suzy V. Torti, E.L. Kwak, Shannon C. Miller et al. · Journal of Biological Chemistry · 1988 · 298 citations · Full text

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066

E.L. Kwak, D. Ross Camidge, John L. Clark et al. · Journal of Clinical Oncology · 2009 · 202 citations

Cancer Management, Cancer Pharmacology, Pharmacotherapy +22

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC).

D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak et al. · Journal of Clinical Oncology · 2011 · 135 citations

Progression-free Survival, Alk-positive Nsclc, Part 2 +14

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).

Y. Bang, E.L. Kwak, Alice T. Shaw et al. · Journal of Clinical Oncology · 2010 · 135 citations

Pharmacotherapy, Pre-clinical Pharmacology, Neuro-oncology +18